

2. Abbas *et al.*, "The Complement System", pp. 293-316 from Cellular and Molecular Immunology, 1994, Saunders, Philadelphia.
3. Bryant and Hogue, "Structural Neighbors and Structural Alignments: The Science Behind Entrz/3D", NCBI Staff Publication, August 1996.
4. Tabulation of Protein Data Bank depicting PDB content growth from 1972 to 2001.
5. Clayman *et al.*, "Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers," *Clinical Cancer Research*, 5:1715-1722, July 1999.
6. Stewart *et al.*, "Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial," *Gene Therapy*, 6:350-363, March 1999.
7. Abstract to Stewart *et al.*, indicating month of publication as March, 1999.

#### IN THE CLAIMS

The claims of the application have been amended herein as indicated in the following marked up copies of the claims.

1. (Amended) A recombinant vector which is replication-restricted to neoplastic cells [replication-competent in a neoplastic cell] and which overexpresses an adenovirus death protein.
2. (Amended) The recombinant vector of claim 1 wherein the adenovirus death protein comprises amino acids 1-26, 41-59, and 63-70 of either SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7[,] or SEQ ID NO:8, or a conservatively substituted variant thereof; or  
wherein the adenovirus death protein comprises SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.
5. (Amended) The recombinant vector of claim 4, wherein the recombinant virus [which] comprises SEQ ID NO:3 or SEQ ID NO:4.
10. (Amended) A method for promoting death of a neoplastic cell comprising contacting the neoplastic cell with at least one vector, wherein said vector is replication-restricted to neoplastic cells and [which is replication competent in the neoplastic cell and which] overexpresses an adenovirus death protein.

11. (Amended) The method of claim 10 wherein the adenovirus death protein comprises amino acids 1-26, 41-59, and 63-70 of either SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7[,] or SEQ ID NO:8, or a conservatively substituted variant thereof; or

wherein the adenovirus death protein comprises SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.

13. (Amended) The method of claim 12, wherein the neoplastic cell is contained in [comprises] a tumor in a patient and the contacting step comprises administering the vector [recombinant adenovirus] to neoplastic cells of the tumor, wherein the vector comprises a recombinant adenovirus

21. (Amended) The method of claim 20 comprising administering more than one distinct type of recombinant adenovirus to the tumor and treating the tumor with radiation, wherein at least one recombinant adenovirus is replication-defective.

24. (Amended) The method of claim 13, further comprising administering to the tumor one or more replication-defective adenovirus which expresses an anti-cancer gene product, wherein the recombinant adenovirus facilitates the [complements] spread of the replication-defective adenovirus in the tumor.